Preclinical data suggested that, in the presence of human epidermal growth factor receptor (HER)-3-altered activation, colorectal cancer cells may escape anti-epidermal growth factor receptor (EGFR)-mediated cell death. HER-3 overexpression may then represent a key factor for resistance to anti-EGFR antibodies in colorectal cancer. The aim of our analysis was to investigate a possible correlation between HER-3 expression and clinical outcome in wild-type K-RAS advanced colorectal cancer patients receiving cetuximab and irinotecan. We retrospectively analyzed immunoreactivity for HER-3 in wild-type K-RAS advanced colorectal cancer patients receiving irinotecan and cetuximab. Eighty-four advanced wild-type K-RAS colorectal cancer patients were available for HER-3 analysis. Forty patients (48\%) had a HER-3(-) colorectal tumor, whereas the remaining 44 cases (52\%) were deemed HER-3(+). In patients with HER-3(-) and HER-3(+) tumors, we observed a partial response in 17 (42\%) and eight (18\%) patients respectively; progressive disease occurred in 11 (35\%) and 26 (53\%) patients with HER-3(-) and HER-3(+) tumors, respectively (p = .003). The median progression-free survival time was 6.3 months in patients with HER-3(-) tumors and 2.8 months for those who had HER-3-overexpressing tumors (p < .0001). The median overall survival time was 13.6 months in patients showing HER-3(-) tumors and 10.5 months for those who had HER-3-expressing tumors (p = .01). HER-3 proved to be a predictive factor for clinical outcome in wild-type K-RAS colorectal cancer patients treated with cetuximab. Combined HER-3 and K-RAS analysis may represent an effective strategy for better selection of responding colorectal cancer patients.

The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab / Scartozzi, M.; Mandolesi, A.; Giampieri, R.; Bittoni, A.; Pierantoni, C.; Zaniboni, A.; Galizia, E.; Giustini, L.; Silva, R. R.; Bisonni, R.; Berardi, R.; Biscotti, T.; Biagetti, S.; Bearzi, I.; Cascinu, Stefano. - In: THE ONCOLOGIST. - ISSN 1083-7159. - 16:(2011), pp. 53-60. [10.1634/theoncologist.2010-0119]

The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.

CASCINU, Stefano
2011

Abstract

Preclinical data suggested that, in the presence of human epidermal growth factor receptor (HER)-3-altered activation, colorectal cancer cells may escape anti-epidermal growth factor receptor (EGFR)-mediated cell death. HER-3 overexpression may then represent a key factor for resistance to anti-EGFR antibodies in colorectal cancer. The aim of our analysis was to investigate a possible correlation between HER-3 expression and clinical outcome in wild-type K-RAS advanced colorectal cancer patients receiving cetuximab and irinotecan. We retrospectively analyzed immunoreactivity for HER-3 in wild-type K-RAS advanced colorectal cancer patients receiving irinotecan and cetuximab. Eighty-four advanced wild-type K-RAS colorectal cancer patients were available for HER-3 analysis. Forty patients (48\%) had a HER-3(-) colorectal tumor, whereas the remaining 44 cases (52\%) were deemed HER-3(+). In patients with HER-3(-) and HER-3(+) tumors, we observed a partial response in 17 (42\%) and eight (18\%) patients respectively; progressive disease occurred in 11 (35\%) and 26 (53\%) patients with HER-3(-) and HER-3(+) tumors, respectively (p = .003). The median progression-free survival time was 6.3 months in patients with HER-3(-) tumors and 2.8 months for those who had HER-3-overexpressing tumors (p < .0001). The median overall survival time was 13.6 months in patients showing HER-3(-) tumors and 10.5 months for those who had HER-3-expressing tumors (p = .01). HER-3 proved to be a predictive factor for clinical outcome in wild-type K-RAS colorectal cancer patients treated with cetuximab. Combined HER-3 and K-RAS analysis may represent an effective strategy for better selection of responding colorectal cancer patients.
16
53
60
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab / Scartozzi, M.; Mandolesi, A.; Giampieri, R.; Bittoni, A.; Pierantoni, C.; Zaniboni, A.; Galizia, E.; Giustini, L.; Silva, R. R.; Bisonni, R.; Berardi, R.; Biscotti, T.; Biagetti, S.; Bearzi, I.; Cascinu, Stefano. - In: THE ONCOLOGIST. - ISSN 1083-7159. - 16:(2011), pp. 53-60. [10.1634/theoncologist.2010-0119]
Scartozzi, M.; Mandolesi, A.; Giampieri, R.; Bittoni, A.; Pierantoni, C.; Zaniboni, A.; Galizia, E.; Giustini, L.; Silva, R. R.; Bisonni, R.; Berardi, R.; Biscotti, T.; Biagetti, S.; Bearzi, I.; Cascinu, Stefano
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1079285
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 49
social impact